Eris Lifesciences has announced the formation of a strategic alliance with Natco Pharma to launch semaglutide in the Indian pharmaceutical market. This partnership marks a significant step in expanding diabetes treatment options available to Indian patients.

Strategic Partnership Details

The alliance between Eris Lifesciences and Natco Pharma focuses specifically on bringing semaglutide to the Indian market. This collaboration combines the strengths of both pharmaceutical companies to address the growing demand for advanced diabetes treatments in India.

Market Implications

The introduction of semaglutide through this strategic alliance represents an important development in India's diabetes care landscape. Semaglutide is a significant therapeutic option for diabetes management, and this partnership aims to make it accessible to Indian patients through the combined expertise of both companies.

Company Positioning

This strategic alliance strengthens Eris Lifesciences' portfolio in the diabetes treatment segment while leveraging Natco Pharma's capabilities in pharmaceutical development and manufacturing. The partnership demonstrates both companies' commitment to addressing critical healthcare needs in the Indian market.

Eris Lifesciences Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showcasing steady growth in its pharmaceutical business. The Board of Directors approved the results in their meeting held on February 13, 2026, followed by an investor presentation under Regulation 30.

Financial Performance Overview

The company delivered robust performance across key financial metrics during the third quarter of FY26. Revenue growth was driven primarily by increased product sales, while the company maintained its focus on operational efficiency.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Eris Lifesciences demonstrated consistent growth momentum. The company's consolidated revenue from operations increased to ₹2,372.86 crore from ₹2,188.34 crore in the corresponding period of the previous year.

Domestic Branded Formulations Segment

The Domestic Branded Formulations (DBF) segment showed strong performance with revenue of ₹696 crore in Q3 FY26, representing 10% year-over-year growth. The nine-month DBF revenue reached ₹2,106 crore, up 10% from the previous year.

International Business Growth

The international business segment delivered exceptional performance with Q3 revenue of ₹111 crore, marking 45% year-over-year growth. This represents the strongest quarterly performance for the segment. The nine-month international revenue stood at ₹259 crore with 11% growth.

Impact of New Labour Codes

The company recorded exceptional items of ₹17.24 crore during Q3 FY26 due to the implementation of new labour codes by the Government of India, effective November 21, 2025. These codes consolidated multiple existing labour legislations into a unified framework, resulting in increased gratuity and leave liabilities arising from changes in the definition of "wages" for employees and contract labours.

Corporate Actions and Developments

Subsequent to the quarter end, on January 16, 2026, the company completed a significant transaction involving Swiss Parenterals Limited. Eris Lifesciences allotted 23,06,372 fully paid-up equity shares at an issue price of ₹1835.35 per share through private placement, acquiring the remaining 30% stake in Swiss Parenterals Limited, making it a wholly-owned subsidiary.

Key Financial Ratios

The company maintained healthy financial ratios during the quarter, showing improved capital structure management.

The company's debt-equity ratio improved to 0.67 times from 0.79 times in the previous year, indicating better capital structure management. The interest service coverage ratio strengthened to 4.33 times, reflecting improved earnings relative to finance costs.

Analyst and Investor Call Transcript

On February 20, 2026, Eris Lifesciences informed the stock exchanges that the transcript of the analyst and investor call held after the announcement of Q3 FY26 financial results is now available on the company's website. The transcript can be accessed at the company's official website under the financials section, providing detailed insights into the quarterly performance and management commentary on business outlook.